Skip to main content

Algo TX/IOCPC23007/ Gewandter

Basic Study Information

The purpose of this clinical trial is to compare the efficacy of twice daily applications of ATX01 (10% & 15%) versus placebo during a 12-week treatment period in treating chemotherapy-induced peripheral neuropathy (CIPN) in adult cancer survivor patients.

Location: University of Rochester Medical Center

Lead Researcher (Principal Investigator)

Lead Researcher:  Jennifer Gewandter

Study Contact Information

Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email:

Additional Study Details

Return to Search